Cyclacel Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Spiro Rombotis
Chief executive officer
US$661.0k
Total compensation
| CEO salary percentage | 84.7% |
| CEO tenure | 27.3yrs |
| CEO ownership | 1.5% |
| Management average tenure | no data |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$18m |
| Mar 31 2024 | n/a | n/a | -US$20m |
| Dec 31 2023 | US$661k | US$560k | -US$23m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$23m |
| Dec 31 2022 | US$764k | US$546k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$20m |
| Dec 31 2021 | US$1m | US$531k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$1m | US$531k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$1m | US$531k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$8m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$753k | US$531k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$776k | US$531k | -US$15m |
Compensation vs Market: Spiro's total compensation ($USD661.05K) is above average for companies of similar size in the German market ($USD483.75K).
Compensation vs Earnings: Spiro's compensation has been consistent with company performance over the past year.
CEO
Spiro Rombotis (65 yo)
27.3yrs
Tenure
US$661,049
Compensation
Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Pharmaceuticals, Inc. (formerly known as Cyclacel Group plc)) since August 1997 and has been its Founding C...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 18.7yrs | US$661.05k | 1.52% € 11.6k | |
| Executive VP of Finance | 18.7yrs | US$352.62k | 0.82% € 6.3k | |
| Chief Medical Officer & Director | 3.9yrs | US$84.49k | 0.85% € 6.5k | |
| Independent Chair of the Board | 10.2yrs | US$97.99k | 0.21% € 1.6k | |
| Independent Director | 18.7yrs | US$136.99k | 0.21% € 1.6k | |
| Independent Director | 4yrs | US$95.49k | 0.21% € 1.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Vice Chairman | 6.2yrs | US$115.99k | 0.21% € 1.6k | |
| Independent Director | 2.4yrs | US$85.49k | 0.20% € 1.5k |
8.2yrs
Average Tenure
68yo
Average Age
Experienced Board: UXI's board of directors are considered experienced (8.2 years average tenure).